A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine
about
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineAlkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistanceShould we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityWild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidineA novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutationsGenotypic testing for human immunodeficiency virus type 1 drug resistance.Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.The "Connection" Between HIV Drug Resistance and RNase HVirulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations.HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excisionFailure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensMutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistanceA Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitorsA counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selectionHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTBisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 2Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.
P2860
Q24535740-3DC20CCE-21FB-44A9-82DB-8D98EC049EFFQ28343476-68BE1320-1EB1-4122-BD29-48122C186F9CQ28365182-A4EDEEF9-0140-4419-95E9-246FEEBEA263Q28471687-1F7E179F-FC6A-4BE6-92F5-9C245A381677Q28471689-F020FC5B-2E50-4D45-ADE5-91E31C477563Q28533996-E9B66ECB-632B-43C0-927A-5EC205321E89Q33808236-76D8D483-A2FA-422B-B7C3-7A630941FF6FQ33826904-8387E3EE-DD10-4354-8EBC-4206078BAFBAQ33869951-7D781E3F-7ED1-4883-95C2-A4C1BCD6EDD0Q33906239-08893299-3CE2-4A36-8B92-63E863520772Q34079002-E8074308-8620-4C91-AAC1-947DCDE29070Q34193340-DB4B65ED-FBFB-4D80-B18D-255C64A7E4C1Q34251987-F89191D1-6EB7-454E-8EC4-6431F78FA2B8Q34303603-5B4222C2-9B9F-4558-BEA8-48A5841E2C0DQ34313605-45A821A6-C25B-4665-8E0D-229A75641249Q34339657-C6D9CE38-9316-4136-BEAA-A19179063BD9Q34681252-56282B9F-0D8C-4256-8664-626ACC6B2B26Q34746064-DF52CCDB-D5A7-4DD8-88D1-9AEEFC2D990BQ34802871-90A14ABC-44FA-4C19-805A-581BF90D2848Q34916002-99E332BE-209A-4F7D-A2FA-B0D4FE88F7BFQ35004847-1BCE9A65-CBA3-4AF7-8CF9-C6A53547123AQ35576015-4196EDDC-2B02-4359-97CA-3A6710892D5CQ35742512-D5234655-C41A-4643-B3DD-E8A18F5D0666Q35947607-82D0C9C1-D075-4EE5-B814-75FF86129C7DQ36347325-01651AF6-A472-4A59-A972-BA5FB9968804Q36498272-4A6BC10A-9B32-42DD-BE50-5EFB2B284EB9Q36629197-C608BB9A-AA42-42C2-840C-649859B62657Q36900010-75213BE9-5B86-4A35-B634-B36AFCD2E1E0Q36981369-5BD152B9-697F-41B0-B211-FD13495AA37EQ37018369-930D8357-DFEC-4C40-AAE0-CB247BD6FA30Q37333826-6F3AFCBE-05ED-41B8-B58C-5105632DA6CFQ37338779-C49D9E6A-2E1D-47F4-9C7E-612C38FA2715Q39461924-3EF56FEF-E07D-471A-8DE7-501A4DBD6821Q39471491-0F49C73F-3223-48DF-BD99-D5C5DBFE233EQ39591902-12097240-49B9-4909-95A1-B2A7432FC04BQ39652295-BB0DAF49-A198-454D-9371-C77166D2A7EAQ39730755-32E30D39-17CC-42CF-96CF-A91313627601Q41262484-AF691931-F498-4315-832F-78CEC0F3B016Q41912300-2B5761E4-4658-4E7A-A538-FB8F75CEB967Q42159090-4C204119-2C4F-4931-A5F0-3DEEE50C290F
P2860
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@ast
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@en
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@nl
type
label
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@ast
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@en
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@nl
prefLabel
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@ast
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@en
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@nl
P2093
P2860
P1433
P1476
A novel polymorphism at codon ...... -2',3'-dideoxy-3'-thiacytidine
@en
P2093
P2860
P304
P407
P577
1998-06-01T00:00:00Z